Prostate MR AI (VA10A)

Oncology Radiology Urology

Contact for pricing
Regulatory Status Disclosed

Overview

Prostate MR AI (VA10A) by Siemens Healthineers is a Radiological Computer Assisted Detection and Diagnosis Software (CADe/CADx) designed to enhance prostate MRI reading and reporting. It leverages artificial intelligence to assist radiologists in the interpretation of multiparametric Prostate MRI examinations, particularly those acquired according to the PI-RADS standard. The tool aids in the detection and classification of suspicious prostate lesions and can generate a pre-populated report. It automatically segments the prostate gland and marks its outer contour, significantly reducing the time required for manual contouring. The results, including lesion candidates and suspicion maps, can be exported in RTSS format, facilitating targeted MR-US fusion biopsies by urologists. This solution aims to streamline workflows, reduce the burden of routine tasks for radiologists, and support more informed clinical decision-making for prostate cancer diagnosis and treatment planning.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Lesion candidate localization and classification
  • Pre-populated PI-RADS report generation
  • Prostate gland segmentation and volumetric assessment
  • Suspicion map highlighting lesion candidates
  • Export results in RTSS format for TRUS-guided biopsy
  • Automatic prostate contouring
  • Manual contouring manipulation and annotation
  • Calculation of PSA density
  • DICOM compliant
  • Cloud-based image processing software

Use Cases

  • Prostate MRI reading and reporting
  • Interpretation of multiparametric Prostate MRI
  • Detection and classification of prostate lesions
  • Facilitating targeted MR-US fusion biopsies
  • Reducing radiologist workload by automating routine tasks
  • Supporting clinical decision-making for prostate cancer

Details

Category Oncology AI, Radiology & Imaging AI, Surgical AI
Pricing Contact for pricing Subscription-based SaaS model; 90-day trial license available for AI-Rad Companion family products.
DeploymentHybrid (locally on dedicated hardware/virtualized, and cloud-based via teamplay platform)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status 1 AI-estimated

Prostate MR AI (VA10A) received FDA clearance (K241770) as Radiological Computer Assisted Detection and Diagnosis Software (CADe/CADx). The FDA determined it is substantially equivalent to legally marketed predicate devices, allowing it to be marketed under the Federal Food, Drug, and Cosmetic Act.

Integrations
EHR Not specified
Specialties Oncology, Radiology, Urology

What the Web Says

Siemens Healthineers' Prostate MR AI (VA10A) is an FDA-cleared AI-powered solution designed to assist radiologists in interpreting multiparametric MRI images of the prostate. It aims to improve the detection and classification of prostate lesions, reduce reading times, and enhance reporting consistency. The tool functions as a concurrent reading aid, providing automated segmentation of the prostate and facilitating targeted MR/US-fusion biopsies.

Overall: Positive

Strengths

  • Increases inter-reader concordance by 63% and reduces median reading time by 21%.
  • Improves lesion assessment accuracy, especially for less-experienced radiologists, bringing their performance closer to that of experienced radiologists.
  • Automates prostate segmentation and volume measurement, providing consistent gland outlining.
  • Assists in reporting consistency by providing structured data extraction and reminders for required reporting elements.
  • Facilitates targeted MR/US-fusion biopsies by exporting segmentation results and lesion contours.
  • Can prioritize likely-positive exams in high-volume settings, aiding workflow triage.

Limitations

  • Can generate false positives due to artifacts, prostatitis, or hemorrhage.
  • Accuracy can be reduced by large glands, BPH nodules, or poor image quality.
  • Does not substitute for PI-RADS knowledge or systematic image review.
  • AI performance is dependent on image quality and can be degraded by motion, susceptibility artifacts, and unusual anatomy.
  • Risk of overreliance, where radiologists may tend to confirm rather than question AI output.
  • A model trained on one population or scanner mix may not behave the same way in another practice.

Based on reviews from: vertexaisearch.cloud.google.com, www.siemens-healthineers.com, accessdata.fda.gov, www.innolitics.com

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Prostate MR AI (VA10A)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

accessdata.fda.gov
Prostate MR AI (VA10A) K241770 - FDA 510(k) Premarket Notification
This FDA premarket notification addresses the Siemens Healthineers Prostate MR AI (VA10A) Radiological Computer Assisted Detection and Diagnosis Software (CADe/CADx), designed to assist radiologists in detecting and classifying suspicious lesions in prostate MRI examinations. The plug-in software analyzes non-contrast T2-weighted and diffusion-weighted images to segment the prostate gland and provide automatic detection and segmentation of suspicious regions, along with a PI-RADS interpretation suggestion.
2025-03
Innolitics
Prostate MR AI (VA10A) (K241770) u2014 FDA 510(k) | Innolitics
This entry details the FDA 510(k) clearance for Siemens Healthcare GmbH's Prostate MR AI (VA10A), cleared on March 5, 2025, under product code QDQ for Radiology.
2025-03
Prostate MRI Toolkit
AI in Prostate MRI: Hype, Help, and Hard Limits
This educational article discusses the role of AI in prostate MRI, including tools like Siemens Healthineers' Prostate MR AI VA10A, emphasizing that FDA clearance signifies substantial equivalence, not guaranteed performance in all clinical settings. It highlights that AI tools can assist with lesion detection, prostate segmentation, and reporting consistency, but radiologists should treat them as decision-support layers.
2026-06
Innolitics
Command Line as a Medical Device (CLaMD) - Innolitics
This article mentions Siemens Healthcare GmbH's Prostate MR AI (VA10A) in the context of medical devices that operate without a standalone graphical user interface, functioning as a plug-in device for a separate hosting application.
2025-05
accessdata.fda.gov
510(k) Premarket Notification K253495 - Syngo.MR Applications - FDA
This FDA premarket notification for Syngo.MR Applications mentions that syngo.MR Prostate AI integrates the AI-based algorithm u201cProstate MR AI VA10A (K241770)u201d without modification.
2025-11
FDA.report
Lunit INSIGHT DBT (V1.2) 510(k) K253796 - FDA.report
This regulatory filing lists Prostate MR AI (VA10A) by Siemens Healthcare GmbH, cleared on March 5, 2025, among other 510(k) records for product code QDQ.
2025-03
FDA.gov
K241770 - 510(k) Premarket Notification - FDA
This is the official FDA 510(k) Premarket Notification page for Prostate MR AI (VA10A), listing Siemens Healthcare GmbH as the applicant and Abhineet Johri as the contact.
2026-01

Videos

Product demos, reviews, and walkthroughs for Prostate MR AI (VA10A).

View all on YouTube

Frequently Asked Questions

Siemens Healthineers Prostate MR AI (VA10A), also known as AI-Rad Companion Prostate MR for Biopsy Support, automatically segments the prostate gland and marks its outer contour, significantly reducing manual segmentation time. It assists radiologists in detecting and classifying suspicious lesions on multiparametric MRI, providing a lesion score and visualization for targeted MR/US-fusion biopsies.
Siemens Healthineers Prostate MR AI (VA10A) has received FDA clearance in the U.S. and is CE-marked for use in Europe, confirming its compliance as a medical device. This ensures it meets established safety and performance standards for clinical application.
While AI tools like VA10A demonstrate performance comparable to experienced radiologists, they are intended as support tools rather than replacements for human interpretation. Current AI solutions for prostate MRI typically focus on identifying lesions within the prostate gland and do not identify distant disease such as nodal or bony involvement. Patient management decisions should not be made solely based on AI analysis.
Studies indicate that AI systems like VA10A can achieve diagnostic performance comparable to or even superior to radiologists, particularly in detecting clinically significant prostate cancer. It has been shown to improve mean detection performance, reduce inter-reader variability, and decrease reading time for radiologists.
Several other vendors offer AI tools for prostate MRI analysis, including Lucida Medical, Deephealth, and Quibim. These platforms also aim to detect and segment suspicious prostate lesions, often trained on large datasets with histological correlation.
Pricing models for AI systems in radiology can vary, often tied to the number of examinations performed or the availability of specific features. These costs are in addition to conventional reporting, and adoption may depend on potential reimbursement for automated diagnostics or gains in reporting speed and accuracy. Cloud-based services might offer less hardware footprint and potentially mitigate initial installation costs.
For cloud-based AI services, the transmission of patient data requires careful consideration and clearance from the site's data protection authority and data security office. Ensuring compliance with regulations like DICOM and potentially FHIR standards is crucial for interoperability and secure handling of sensitive patient information.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Siemens Healthineers

AI-Rad Companion (Pulmonary)
Siemens Healthineers
Radiology & Imaging AI
AI-Rad Companion (Pulmonary) by Siemens Healthineers is an AI-powered image processing software for quantitative and qualitative analysis of lung CT images, aiding physicians in evaluating and assessing pulmonary diseases.
AI-Rad Companion Organs RT
Siemens Healthineers
Oncology AI
AI-Rad Companion Organs RT by Siemens Healthineers is an AI-powered software that automates the contouring of organs at risk (OARs) on CT and MR images for radiation therapy planning, aiming to improve efficiency and consistency.
Biograph Horizon
Siemens Healthineers
Neurology AI
The Siemens Healthineers Biograph Horizon is an advanced PET/CT medical imaging system that combines PET and CT scans for comprehensive diagnostic information in oncology, neurology, and cardiology. It is not an AI tool for a physician directory.
Biograph Vision
Siemens Healthineers
Cardiology AI
Biograph Vision is a Siemens Healthineers PET/CT imaging system offering high resolution, sensitivity, and ultra-fast time-of-flight performance for precise diagnostics in oncology, cardiology, and neurology, aiming to reduce scan times and patient dose.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.